Changeflow GovPing Pharma & Drug Safety Metalloenzyme Inhibitor Patent for Cancer, Alzh...
Routine Notice Added Final

Metalloenzyme Inhibitor Patent for Cancer, Alzheimer's, Hemochromatosis

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4228628A1 for Miralogx LLC covering a metalloenzyme inhibitor compound (3,5-bis(3,4-dihydro-2H-pyrrol-2-yl)-pyridine) for treating cancer, Alzheimer's disease, and hemochromatosis. The patent is classified under organic chemistry (C07D) with pharmaceutical applications (A61K) and therapeutic uses (A61P). The application designates all EU member states plus other EPC contracting states.

What changed

The European Patent Office published patent application EP4228628A1, filed by Miralogx LLC, covering a novel pyridine-based metalloenzyme inhibitor compound for the treatment of cancer, Alzheimer's disease, and hemochromatosis. The application is classified under IPC class C07D (organic chemistry) with therapeutic applications in oncology and neurology.

This patent grant confers exclusive rights to Miralogx LLC across all designated European Patent Convention contracting states for the 20-year patent term from filing. Pharmaceutical companies and researchers developing metalloenzyme inhibitors for these therapeutic indications should conduct freedom-to-operate analyses to assess potential infringement risks in EU markets.

What to do next

  1. Monitor for updates on patent prosecution progress
  2. Review freedom-to-operate implications if developing similar inhibitors
  3. Evaluate licensing opportunities for the designated EU territories

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

3,5-BIS(3,4-DIHYDRO-2H-PYRROL-2-YL)-PYRIDINE AS A METALLOENZYME INHIBITOR FOR THE TREATMENT OF CANCER, ALZHEIMER'S DISEASE AND HEMOCHROMATOSIS

Publication EP4228628A1 Kind: A1 Apr 01, 2026

Applicants

Miralogx LLC

Inventors

WILLIAMS, Jonnie, R.

IPC Classifications

C07D 401/04 20060101AFI20240920BHEP A61K 31/4439 20060101ALI20240920BHEP A61P 35/00 20060101ALI20240920BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4228628A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent licensing IP management
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!